Newsroom
-
October 30 , 2023
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Read more -
October 30 , 2023
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Read more -
October 12 , 2023
MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech on the development of a next-generation antibody-drug conjugate candidate (“ADC”), against Human Epidermal Growth Factor Receptor 3 (HER3)
Read more -
July 7 , 2021
Rare genetic variants confer largest increase in type 2 diabetes risk seen to date
- Scientists at the University of Cambridge have identified rare genetic variants—carried by one in 3,000 people—that have a larger impact on the risk of developing type 2 diabetes than any previously identified genetic effect.
Read more -
July 6 , 2021
Researchers discover way to improve immune response
- Melbourne researchers have identified a way to improve the immune response in the face of severe viral infections.
Read more